Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Senti Biosciences Holdings, Inc.SNTI · Entity 7935 | Director · CEO | March 09, 2026 | March 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Senti Biosciences Holdings, Inc.
Report date March 09, 2026 · Filed March 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 639,583 |
Reported balance
After 2026-03-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-09 · Tax withholding · Disposed 80,666 · Balance 639,583 F1: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 52,839 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 52,839 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 52,839 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 52,839 F2: The shares are held by Luminen Services, LLC, as trustee of the Luminen Trust, of which the reporting person is the settlor. The reporting person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.
F2: The shares are held by Luminen Services, LLC, as trustee of the Luminen Trust, of which the reporting person is the settlor. The reporting person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2026 Filed Mar 11, 2026 20:01 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | Tax withholdingCommon Stock | 80,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-016794 · wk-form4_1773259287.xml · nonDerivative · entry 1 Lu Timothy K · CIK 0001852301 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 639,583 F1 · shares: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale. F1 · ownership.direct: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:16 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | Tax withholdingCommon Stock | 4,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-005014 · wk-form4_1770153401.xml · nonDerivative · entry 1 Lu Timothy K · CIK 0001852301 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,249 F1 · shares: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale. F1 · balance_after: Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 23:01 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantCommon Stock | 642,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001854270-25-000013 · wk-form4_1741647685.xml · nonDerivative · entry 1 Lu Timothy K · CIK 0001852301 · Director · CEO and Interim PFO and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 724,440 F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan, as amended and restated (the "Amended and Restated Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from March 7, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:01 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 1,927,073 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001854270-25-000013 · wk-form4_1741647685.xml · derivative · entry 4 Lu Timothy K · CIK 0001852301 · Director · CEO and Interim PFO and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,927,073 Underlying: Common Stock · 1,927,073 shares Expires 2034-12-19 F3 · date: The option grant was approved by the Issuer's board of directors on December 20, 2024, subject to shareholder approval of the Amended and Restated Plan, under which the option was granted. The Issuer's shareholders approved the Amended and Restated Plan on March 6, 2025. F4 · derivative.exercise_date: Three-forty-eighth of the shares underlying this option vest on March 31, 2025 ("Vesting Commencement Date") and thereafter one-forty-eighth of the shares underlying this option vest in equal monthly installments from the Vesting Commencement Date, such that the option will be fully vested on the date forty-five months after the Vesting Commencement Date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 01:23 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | SaleCommon Stock | 545 | $4.36 | $2,376.20 |
DisclosureSEC source: 0001854270-25-000004 · wk-form4_1738891411.xml · nonDerivative · entry 2 Lu Timothy K · CIK 0001852301 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,082 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| February 04, 2025 Filed Feb 7, 2025 01:23 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | SaleCommon Stock | 3,922 | $4.07 | $15,962.54 |
DisclosureSEC source: 0001854270-25-000004 · wk-form4_1738891411.xml · nonDerivative · entry 1 Lu Timothy K · CIK 0001852301 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,627 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 22:27 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 459,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001854270-24-000015 · wk-form4_1706912814.xml · derivative · entry 4 Lu Timothy K · CIK 0001852301 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 459,000 Underlying: Common Stock · 459,000 shares Expires 2034-01-31 F3 · derivative.exercise_date: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 22:27 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantCommon Stock | 306,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001854270-24-000015 · wk-form4_1706912814.xml · nonDerivative · entry 1 Lu Timothy K · CIK 0001852301 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 865,496 F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:20 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 630,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001854270-23-000017 · wf-form4_167537640361956.xml · derivative · entry 1 Lu Timothy K · CIK 0001852301 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,000 Underlying: Common Stock · 630,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.